将纳米药物递送至实体瘤。
Delivering nanomedicine to solid tumors.
机构信息
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA.
出版信息
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64. doi: 10.1038/nrclinonc.2010.139. Epub 2010 Sep 14.
Abstract
Recent advances in nanotechnology have offered new hope for cancer detection, prevention, and treatment. While the enhanced permeability and retention effect has served as a key rationale for using nanoparticles to treat solid tumors, it does not enable uniform delivery of these particles to all regions of tumors in sufficient quantities. This heterogeneous distribution of therapeutics is a result of physiological barriers presented by the abnormal tumor vasculature and interstitial matrix. These barriers are likely to be responsible for the modest survival benefit offered by many FDA-approved nanotherapeutics and must be overcome for the promise of nanomedicine in patients to be realized. Here, we review these barriers to the delivery of cancer therapeutics and summarize strategies that have been developed to overcome these barriers. Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors.
摘要
近年来，纳米技术的进展为癌症的检测、预防和治疗带来了新的希望。虽然增强的通透性和保留效应是使用纳米颗粒治疗实体瘤的关键原理，但它不能使这些颗粒以足够的数量均匀地输送到肿瘤的所有区域。治疗剂的这种不均匀分布是由异常肿瘤血管和细胞外基质引起的生理屏障造成的。这些屏障可能是许多获得 FDA 批准的纳米药物提供的适度生存获益的原因，必须克服这些屏障，才能使纳米医学在患者中得以实现。在这里，我们回顾了癌症治疗药物传递的这些障碍，并总结了已开发出的克服这些障碍的策略。最后，我们讨论了优化纳米颗粒向肿瘤传递的设计考虑因素。
相似文献
1
Delivering nanomedicine to solid tumors.将纳米药物递送至实体瘤。
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64. doi: 10.1038/nrclinonc.2010.139. Epub 2010 Sep 14.
2
Design considerations for nanotherapeutics in oncology.肿瘤学中纳米治疗药物的设计考量
Nanomedicine. 2015 Nov;11(8):1893-907. doi: 10.1016/j.nano.2015.07.015. Epub 2015 Aug 15.
3
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.基质屏障以及纳米药物递送治疗促结缔组织增生性肿瘤的策略
J Control Release. 2015 Dec 10;219:192-204. doi: 10.1016/j.jconrel.2015.08.017. Epub 2015 Aug 12.
4
Cancer nanomedicine: mechanisms, obstacles and strategies.癌症纳米医学：机制、障碍与策略。
Nanomedicine (Lond). 2018 Jul;13(13):1639-1656. doi: 10.2217/nnm-2018-0007. Epub 2018 Jul 23.
5
Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles.重塑肿瘤血管以增强中尺寸纳米颗粒的递送。
ACS Nano. 2015 Sep 22;9(9):8689-96. doi: 10.1021/acsnano.5b02028. Epub 2015 Jul 31.
6
Multistage nanoparticles for improved delivery into tumor tissue.用于改善肿瘤组织递送的多级纳米颗粒。
Methods Enzymol. 2012;508:109-30. doi: 10.1016/B978-0-12-391860-4.00006-9.
7
Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer.纳米医学在透明质酸-CD44 相互作用和信号转导的药理学靶向中的进展和优势。
Adv Cancer Res. 2014;123:277-317. doi: 10.1016/B978-0-12-800092-2.00011-3.
8
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.纳米医学药物递送增强通透性和保留效应在肿瘤学中的挑战和关键考虑因素。
Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.
9
Nanoparticle delivery of cancer drugs.癌症药物的纳米颗粒递药系统。
Annu Rev Med. 2012;63:185-98. doi: 10.1146/annurev-med-040210-162544. Epub 2011 Sep 1.
10
Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.肿瘤酸度裂解马来酸酰胺（TACMAA）：设计智能纳米粒子克服癌症纳米医学中输送障碍的强大工具。
Acc Chem Res. 2018 Nov 20;51(11):2848-2856. doi: 10.1021/acs.accounts.8b00195. Epub 2018 Oct 15.
引用本文的文献
1
Computational Modelling of Cancer Nanomedicine: Integrating Hyperthermia Treatment Into a Multiphase Porous-Media Tumour Model.癌症纳米药物的计算建模：将热疗治疗整合到多相多孔介质肿瘤模型中。
Int J Numer Method Biomed Eng. 2025 Aug;41(8):e70074. doi: 10.1002/cnm.70074.
2
Enhancing targeted delivery and efficacy of PEGylated liposomal doxorubicin with liposomal minoxidil: comprehensive in silico, in vitro, and in vivo tumor model studies.用米诺地尔脂质体增强聚乙二醇化脂质体阿霉素的靶向递送和疗效：全面的计算机模拟、体外和体内肿瘤模型研究
Drug Deliv. 2025 Dec;32(1):2536802. doi: 10.1080/10717544.2025.2536802. Epub 2025 Aug 3.
3
Cell Carriers for Oncolytic Virus Delivery: Prospects for Systemic Administration.用于溶瘤病毒递送的细胞载体：全身给药的前景
Cancers (Basel). 2025 Jul 10;17(14):2296. doi: 10.3390/cancers17142296.
4
Harnessing 3D cell models and high-resolution imaging to unveil the mechanisms of nanoparticle-mediated drug delivery.利用3D细胞模型和高分辨率成像揭示纳米颗粒介导的药物递送机制。
Front Bioeng Biotechnol. 2025 Jul 7;13:1606573. doi: 10.3389/fbioe.2025.1606573. eCollection 2025.
5
Machine learning enabled multiscale model for nanoparticle margination and physiology based pharmacokinetics.基于机器学习的纳米颗粒边缘化和生理学药代动力学多尺度模型
Comput Chem Eng. 2025 Jul;198. doi: 10.1016/j.compchemeng.2025.109081. Epub 2025 Mar 9.
6
The Emerging Role of Extracellular Vesicle-Derived lncRNAs and circRNAs in Tumor and Mesenchymal Stem Cells: The Biological Functions and Potential for Clinical Application.细胞外囊泡衍生的长链非编码RNA和环状RNA在肿瘤及间充质干细胞中的新兴作用：生物学功能及临床应用潜力
Cancers (Basel). 2025 Jun 28;17(13):2186. doi: 10.3390/cancers17132186.
7
Tumor Microvessels with Specific Morphology as a Prognostic Factor in Esophageal Squamous Cell Carcinoma.具有特定形态的肿瘤微血管作为食管鳞状细胞癌的预后因素
Ann Surg Oncol. 2025 Jul 10. doi: 10.1245/s10434-025-17747-2.
8
Machine Learning-Enhanced Nanoparticle Design for Precision Cancer Drug Delivery.用于精准癌症药物递送的机器学习增强型纳米颗粒设计
Adv Sci (Weinh). 2025 Aug;12(30):e03138. doi: 10.1002/advs.202503138. Epub 2025 Jun 19.
9
Extracellular vesicles as missiles for enhanced anti-tumor efficacy of oncolytic viruses: from disseminating oncolysis and anti-tumor immunity to targeted delivery.细胞外囊泡作为增强溶瘤病毒抗肿瘤疗效的“导弹”：从传播溶瘤作用和抗肿瘤免疫到靶向递送
Cell Commun Signal. 2025 Jun 11;23(1):276. doi: 10.1186/s12964-025-02283-z.
10
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.癌症治疗中的纳米医学：从实验室到临床的当前视角
Mol Cancer. 2025 Jun 9;24(1):169. doi: 10.1186/s12943-025-02368-w.
本文引用的文献
1
Diffusion anisotropy in collagen gels and tumors: the effect of fiber network orientation.胶原凝胶和肿瘤中的各向异性扩散：纤维网络取向的影响。
Biophys J. 2010 Nov 17;99(10):3119-28. doi: 10.1016/j.bpj.2010.08.065.
2
Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions.粒子在细胞外基质中的扩散：排斥静电相互作用的影响。
Biophys J. 2010 Sep 8;99(5):1342-9. doi: 10.1016/j.bpj.2010.06.016.
3
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks.同时测量血管网络中的 RBC 速度、流量、血细胞比容和剪切率。
Nat Methods. 2010 Aug;7(8):655-60. doi: 10.1038/nmeth.1475. Epub 2010 Jun 27.
4
Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy.功能化纳米多孔载体中高载量抗体的局部释放用于癌症免疫治疗。
J Am Chem Soc. 2010 May 26;132(20):6906-7. doi: 10.1021/ja102414t.
5
Sustained small interfering RNA delivery by mesoporous silicon particles.介孔硅颗粒持续递送小干扰 RNA。
Cancer Res. 2010 May 1;70(9):3687-96. doi: 10.1158/0008-5472.CAN-09-3931.
6
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.联合使用穿瘤肽可提高癌症药物的疗效。
Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.
7
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.经靶向纳米粒系统给药的 siRNA 在人体中 RNAi 的证据。
Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.
8
Targeting of drugs and nanoparticles to tumors.药物和纳米颗粒对肿瘤的靶向作用。
J Cell Biol. 2010 Mar 22;188(6):759-68. doi: 10.1083/jcb.200910104. Epub 2010 Mar 15.
9
Therapeutic nanoparticles to combat cancer drug resistance.治疗性纳米颗粒对抗癌症耐药性。
Curr Drug Metab. 2009 Oct;10(8):836-41. doi: 10.2174/138920009790274540.
10
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival.使用可激活细胞穿透肽的分子荧光成像引导手术可减少残留肿瘤并改善生存。
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4317-22. doi: 10.1073/pnas.0910261107. Epub 2010 Feb 16.
Zotero 插件